STING1 and ovarian cancer: KRAS-mutant lung cancers are resistant to PD-1/PD-L1 blockade due to the suppression of STING associated with LKB1 loss.131,132 BRCA1-deficient ovarian cancers mediate immune resistance through transcriptional reprogramming and cell-intrinsic inflammation via the STING pathway.133